



an Open Access Journal by MDPI

Advances in Targeting Genomics and the Tumor Immune System to Treat Gastrointestinal Cancers

Guest Editor:

Prof. Dr. Jeeyun Lee

Division of
Hematology/Oncology,
Department of Medicine,
Samsung Medical Center,
Sungkyunkwan University School
of Medicine, 81 Irwon-ro,
Gangnam-gu, Seoul 135-710,
Republic of Korea

Deadline for manuscript
submissions:

closed (31 May 2024)

Message from the Guest Editor

Dear Colleagues,

The majority of cancers are still difficult to treat and the medical need for better cancer treatments is evident. The current anticancer armamentarium includes many active agents that are applied across tumor types. Globally, next-generation sequencing is widely available for oncology patients. However, the clinical implication of genomic aberrations needs to be defined in detail, especially in gastrointestinal oncology area. With the launch of various molecularly targeted agents and immunotargeted agents, subsets of patients with specific genomic aberrations need to be actively discussed and shared within the community. In light of this, we invite research and review papers related to any area of NGS analysis, clinical implications, NGS-based clinical trials in GI oncology and preclinical papers to support further clinical research developments.

We hope that this Special Issue reflects the exciting era that we are living in with respect to the field of clinical genomics oncology, its applications in gastrointestinal cancer treatment, and the targeting of the tumor immune system.

Prof. Dr. Jeeyun Lee
Guest Editor



mdpi.com/si/173543

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI